VISION: An International, Prospective, Open-Label, Multicenter, Randomized Phase 3 Study of 177lu-Psma-617 in the Treatment of Patients with Progressive PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
Endocyte, Inc.
Start Date
January 3, 2019
End Date
February 28, 2024
Administered By
Duke Cancer Institute
Awarded By
Endocyte, Inc.
Start Date
January 3, 2019
End Date
February 28, 2024